IDEXX Laboratories, Inc. (NASDAQ:IDXX) Shares Acquired by Northstar Asset Management Inc.

Northstar Asset Management Inc. lifted its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 0.8% in the third quarter, HoldingsChannel reports. The firm owned 18,904 shares of the company’s stock after buying an additional 158 shares during the period. IDEXX Laboratories makes up about 2.3% of Northstar Asset Management Inc.’s portfolio, making the stock its 21st biggest holding. Northstar Asset Management Inc.’s holdings in IDEXX Laboratories were worth $9,551,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently bought and sold shares of IDXX. Nordea Investment Management AB grew its stake in shares of IDEXX Laboratories by 15.5% in the 1st quarter. Nordea Investment Management AB now owns 13,719 shares of the company’s stock valued at $7,447,000 after buying an additional 1,839 shares during the period. Manning & Napier Advisors LLC purchased a new stake in IDEXX Laboratories in the second quarter valued at $20,418,000. Oppenheimer Asset Management Inc. lifted its stake in shares of IDEXX Laboratories by 13.8% in the 2nd quarter. Oppenheimer Asset Management Inc. now owns 11,957 shares of the company’s stock valued at $5,825,000 after purchasing an additional 1,453 shares during the last quarter. Vanguard Group Inc. grew its holdings in shares of IDEXX Laboratories by 1.2% during the 1st quarter. Vanguard Group Inc. now owns 8,476,054 shares of the company’s stock worth $4,576,476,000 after purchasing an additional 98,387 shares during the period. Finally, EFG Asset Management Americas Corp. increased its position in shares of IDEXX Laboratories by 45.3% during the 2nd quarter. EFG Asset Management Americas Corp. now owns 12,728 shares of the company’s stock worth $6,201,000 after purchasing an additional 3,966 shares during the last quarter. 87.84% of the stock is currently owned by institutional investors and hedge funds.

IDEXX Laboratories Trading Up 0.4 %

NASDAQ IDXX opened at $415.98 on Wednesday. IDEXX Laboratories, Inc. has a 52 week low of $404.74 and a 52 week high of $583.39. The firm has a 50 day moving average of $476.04 and a two-hundred day moving average of $486.32. The company has a quick ratio of 1.03, a current ratio of 1.42 and a debt-to-equity ratio of 0.32. The stock has a market capitalization of $34.24 billion, a PE ratio of 40.11, a price-to-earnings-growth ratio of 3.64 and a beta of 1.36.

IDEXX Laboratories (NASDAQ:IDXX) last issued its earnings results on Thursday, October 31st. The company reported $2.80 EPS for the quarter, topping analysts’ consensus estimates of $2.69 by $0.11. The firm had revenue of $975.50 million during the quarter, compared to the consensus estimate of $980.32 million. IDEXX Laboratories had a net margin of 22.53% and a return on equity of 55.42%. The company’s revenue was up 6.6% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $2.53 earnings per share. As a group, research analysts expect that IDEXX Laboratories, Inc. will post 10.45 EPS for the current fiscal year.

Wall Street Analyst Weigh In

IDXX has been the topic of a number of recent analyst reports. Piper Sandler reaffirmed a “neutral” rating and issued a $435.00 target price (down previously from $520.00) on shares of IDEXX Laboratories in a research report on Monday. StockNews.com downgraded shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a report on Wednesday, July 10th. JPMorgan Chase & Co. decreased their price target on IDEXX Laboratories from $630.00 to $575.00 and set an “overweight” rating on the stock in a research note on Friday, October 11th. Barclays dropped their price objective on IDEXX Laboratories from $570.00 to $481.00 and set an “overweight” rating for the company in a research note on Monday. Finally, Stifel Nicolaus decreased their target price on IDEXX Laboratories from $510.00 to $500.00 and set a “hold” rating on the stock in a research note on Thursday, October 10th. Three investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $552.38.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.